We are live on ! Find out more
RXII

GALENA BIOPHARMA INC COM
RXII

Delisted

RXII was delisted on the 25th of October, 2011.

90 hedge funds and large institutions have $68.9M invested in GALENA BIOPHARMA INC COM in 2014 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 24 increasing their positions, 30 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 16

2% more funds holding

Funds holding: 8890 (+2)

3% more call options, than puts

Call options by funds: $13.7M | Put options by funds: $13.3M

19% less capital invested

Capital invested by funds: $84.7M → $68.9M (-$15.8M)

20% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 30

Holders
90
Holders Change
+2
Holders Change %
+2.27%
% of All Funds
2.59%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
24
Reduced
30
Closed
16
Calls
$13.7M
Puts
$13.3M
Net Calls
+$459K
Net Calls Change
-$3.38M
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
$345K -$130K -42,435 -27%
VOYA Investment Management
27
VOYA Investment Management
Georgia
$317K -$30K -9,818 -9%
RhumbLine Advisers
28
RhumbLine Advisers
Massachusetts
$311K +$47.8K +15,609 +18%
U
29
UBS
Switzerland
$295K -$54.6K -17,799 -16%
HCA
30
Harbour Capital Advisors
Virginia
$295K +$54.8K +17,900 +23%
Wells Fargo
31
Wells Fargo
California
$293K +$84.1K +27,430 +40%
TNB
32
Thomasville National Bank
Georgia
$290K +$290K +95,000 New
NFA
33
Nationwide Fund Advisors
Ohio
$280K +$22.8K +7,436 +9%
MLICM
34
Metropolitan Life Insurance Company (MetLife)
New York
$263K +$29.7K +9,686 +13%
WAM
35
Wolverine Asset Management
Illinois
$246K +$246K +80,400 New
AIG
36
American International Group
New York
$237K +$22.9K +7,469 +11%
Manulife (Manufacturers Life Insurance)
37
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$235K -$3.51K -1,147 -1%
Bank of America
38
Bank of America
North Carolina
$228K -$171K -56,177 -43%
BA
39
BlackRock Advisors
Delaware
$227K -$30.6K -10,021 -12%
CCA
40
Castle Creek Arbitrage
Colorado
$196K
CS
41
Credit Suisse
Switzerland
$189K -$1.1M -358,091 -85%
GC
42
Guggenheim Capital
Illinois
$177K -$5.54K -1,805 -3%
ProShare Advisors
43
ProShare Advisors
Maryland
$176K -$141K -46,024 -44%
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$165K +$164K +53,449 +16,548%
LPL Financial
45
LPL Financial
California
$155K +$4.36K +1,425 +3%
Deutsche Bank
46
Deutsche Bank
Germany
$146K -$1.04M -342,806 -88%
Jane Street
47
Jane Street
New York
$145K +$48.6K +15,893 +50%
T. Rowe Price Associates
48
T. Rowe Price Associates
Maryland
$140K +$140K +45,800 New
Citadel Advisors
49
Citadel Advisors
Florida
$130K -$218K -71,145 -63%
DIA
50
Denver Investment Advisors
Colorado
$120K

RXII Hedge Fund Activity: Q2 2014 in Review

90 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in GALENA BIOPHARMA INC COM (RXII) for Q2 2014, worth a combined $68.9M — down 19% from $84.7M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RXII positions and 16 closed out — a net gain of 3 holders — while 24 added to existing stakes and 30 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.75M. The largest seller was State Street, cutting an estimated $17M.

  • 90 institutional investors held GALENA BIOPHARMA INC COM (RXII) as of Q2 2014, up from 88 in Q1 2014.
  • Funds reported $68.9M of GALENA BIOPHARMA INC COM stock for Q2 2014, down 19% quarter-over-quarter.
  • 19 funds opened new GALENA BIOPHARMA INC COM positions in Q2 2014 and 16 closed out, a net change of +3 holders.
  • The largest GALENA BIOPHARMA INC COM buyer in Q2 2014 was Vanguard Group, an estimated $1.75M added.
  • The largest GALENA BIOPHARMA INC COM seller in Q2 2014 was State Street, an estimated $17M sold.

Based on aggregated 13F filings for Q2 2014.